Cited by 224Liver Disease Diagnosis and TreatmentFatty Acid Research and HealthAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial

Open access

Argo, Curtis K., Patrie, James T., Lackner, Carolin, Henry, Thomas D., de Lange, Eduard E., Weltman, Arthur L., Shah, Neeral L., Al-Osaimi, Abdullah M., Pramoonjago, Patcharin, Jayakumar, Saumya, Binder, Lukas P., Simmons-Egolf, Winsor D., Burks, Sandra G., Bao, Yongde, Taylor, Ann Gill, Rodriguez, Jessica, Caldwell, Stephen H.·2015·Journal of Hepatology

DOI 10.1016/j.jhep.2014.08.036PMC PMC4272639

Open this paper in CoChat — free account

Abstract

Background & aims This study's aim was to assess the histological and metabolic effects of n-3 polyunsaturated fatty acids (PUFAs) vs. placebo while adjusting for the impact of age and weight change in NASH patients. (ClinicalTrials.gov: NCT00681408).Methods Forty-one subjects with non-cirrhotic NASH were enrolled, and 34 completed the study. 17 received n-3 fish oil 3000 mg/day and 17 received placebo daily for 1 year with typical counselling on caloric intake and physical activity for all subjects.Results N-3- and placebo-treated groups showed no significant difference for the primary end point of NASH activity score (NAS) reduction ⩾ 2 points without fibrosis progression after adjustment for known covariates (n-3, 4/17 (23.5%); placebo, 3/17, (17.6%), p = 0.99). Among subjects with increased or stable weight, n-3 subjects showed a larger decrease in liver fat content by MRI than placebo-treated subjects (p = 0.014 for 2nd quartile, p = 0.003 for 3rd quartile of weight change). N-3 treatment showed significant fat reduction on the paired analysis of image-assisted fat morphometry regardless of weight loss or gain. Exercise capacity remained markedly reduced in all subjects. No independent effects on markers of hepatocyte injury or insulin sensitivity indices were observed.Conclusion N-3 PUFAs at 3000 mg/day for one year did not lead to an improvement in the primary outcome of histological activity in NASH patients (⩾ 2 point NAS reduction). N-3 led to reduced liver fat by multiple measures. Other metabolic effects were not seen, although no detrimental effects were apparent. Whether longer duration, higher dose, or different composition of n-3 therapy would lead to additional benefits is uncertain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2014.08.036

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Compendium of physical activities: an update of activity codes and MET intensities
AINSWORTH, B. E., HASKELL, W. L., WHITT, M. C., IRWIN, M. L., SWARTZ, A. M., STRATH, S. J., O???BRIEN, W. L., BASSETT, D. R., SCHMITZ, K. H., EMPLAINCOURT, P. O., et al. (2000) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200009001-00009 · Cited by 8,497
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander‐Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,166
Power and sample size calculations
Dupont, W. D., & Plummer, W. D. (1990) · Controlled Clinical Trials · doi:10.1016/0197-2456(90)90005-m · Cited by 2,112
The Effect of Dietary Supplementation with n—3 Polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells
Endres, S., Ghorbani, R., Kelley, V. E., Georgilis, K., Lonnemann, G., van der Meer, J. W. M., Cannon, J. G., Rogers, T. S., Klempner, M. S., Weber, P. C., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902023200501 · Cited by 1,911
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338

Show all 37 references

Research works printed but not linked: 1

Kleiner, 2008, Creation of a continuous visual scale of ballooned hepatocytes in non-alcoholic fatty liver disease, Hepatology, 48, 815A

Sorted by citations

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2016) · Diabetologia · doi:10.1007/s00125-016-3902-y · Cited by 695
ESPEN guideline on clinical nutrition in liver disease
Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Bischoff, S. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.022 · Cited by 674
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C., Worthington, H. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub3 · Cited by 647
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Past, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 531
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
Lonardo, A., Bellentani, S., Argo, C. K., Ballestri, S., Byrne, C. D., Caldwell, S. H., Cortez‐Pinto, H., Grieco, A., Machado, M. V., Miele, L., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.08.004 · Cited by 452
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C., Worthington, H. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub4 · Cited by 419
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Eriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396
Management of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 393
ESPEN practical guideline: clinical nutrition in liver disease
Bischoff, S. C., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Plauth, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.001 · Cited by 383
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease
Targher, G., & Byrne, C. D. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.16 · Cited by 315
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Anstee, Q. M., Mantovani, A., Tilg, H., & Targher, G. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0010-0 · Cited by 310
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., Summerbell, C. D., Worthington, H. V., Song, F., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub5 · Cited by 295
Gut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 314
Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation
Yang, J., Fernández‐Galilea, M., Martínez‐Fernández, L., González‐Muniesa, P., Pérez-Chávez, A., Martínez, J. A., & Moreno-Aliaga, M. J. (2019) · Nutrients · doi:10.3390/nu11040872 · Cited by 299
Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
Stine, J. G., Munaganuru, N., Barnard, A., Wang, J. L., Kaulback, K., Argo, C. K., Singh, S., Fowler, K. J., Sirlin, C. B., & Loomba, R. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.061 · Cited by 283
Self-citation
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis
Middleton, M. S., Heba, E. R., Hooker, C. A., Bashir, M. R., Fowler, K. J., Sandrasegaran, K., Brunt, E. M., Kleiner, D. E., Doo, E. C., Natta, M. L. V., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.005 · Cited by 278
The Mediterranean dietary pattern as the diet of choice for non‐alcoholic fatty liver disease: Evidence and plausible mechanisms
Zelber‐Sagi, S., Salomone, F., & Mlynarsky, L. (2017) · Liver International · doi:10.1111/liv.13435 · Cited by 273
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Ahn, S. B., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 276
Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)
Fan, J., Wei, L., & Zhuang, H. (2018) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12685 · Cited by 198
Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases
Schunck, W., Konkel, A., Fischer, R., & Weylandt, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.016 · Cited by 211
Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review
Ismaiel, A., & Dumitrascu, D. L. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00202 · Cited by 200
Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Martin, N., Bridges, C., Brainard, J. S., Wang, X., Brown, T. J., Hanson, S., Jimoh, F. O., Ajabnoor, S. M., Deane, K. H., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012345.pub2 · Cited by 194
Pathogenesis and novel treatment options for non-alcoholic steatohepatitis
Wong, V. W., Chitturi, S., Wong, G. L., Yu, J. Q., Chan, H. L., & Farrell, G. C. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30011-5 · Cited by 185
The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups
Chitturi, S., Wong, V. W., Chan, W., Wong, G. L., Wong, S. K., Sollano, J. D., Ni, Y., Liu, C., Lin, Y., Lesmana, L. A., et al. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13856 · Cited by 184
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Cariou, B., Byrne, C. D., Loomba, R. S., & Sanyal, A. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 187
Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action
Scorletti, E., & Byrne, C. D. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.03.001 · Cited by 168
Nonalcoholic Fatty Liver Disease and Obesity Treatment
Brunner, K. T., Henneberg, C. J., Wilechansky, R. M., & Long, M. T. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00345-1 · Cited by 172
A Maresin 1/Rorα/12-Lipoxygenase Autoregulatory Circuit Prevents Inflammation and Progression of Nonalcoholic Steatohepatitis
Han, Y.-H., Shin, K.-O., Kim, J.-Y., Khadka, D. B., Kim, H.-J., Lee, Y.-M., Cho, W.-J., Cha, J.-Y., Lee, B.-J., & Lee, M.-O. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124219 · Cited by 154
Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Martin, N., Bridges, C., Brainard, J. S., Wang, X., Brown, T. J., Hanson, S., Jimoh, F. O., Ajabnoor, S. M., Deane, K. H., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012345.pub3 · Cited by 151
Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease
Hannah, W. N., & Harrison, S. A. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.008 · Cited by 152
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 150
Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials
Zelber‐Sagi, S., Godos, J., & Salomone, F. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16638830 · Cited by 141
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis
Lee, C.-H., Fu, Y., Yang, S., & Chi, C. (2020) · Nutrients · doi:10.3390/nu12092769 · Cited by 148
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
Han, M. A. T., Altayar, O., Hamdeh, S., Takyar, V. K., Rotman, Y., Etzion, O., Lefebvre, E. A., Safadi, R., Ratziu, V., Prokop, L. J., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.06.011 · Cited by 135
Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids
de Castro, G. S., & Calder, P. C. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.01.006 · Cited by 137
Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease
Yan, J., Guan, B., Gao, H., & Peng, X. (2018) · Medicine · doi:10.1097/md.0000000000012271 · Cited by 131
Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
He, X., Wu, X., Chen, R., Chen, C., Liu, X., Wu, B.-J., & Huang, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162368 · Cited by 129
Nutritional therapy for nonalcoholic fatty liver disease
Dongiovanni, P., Lanti, C., Riso, P., & Valenti, L. V. C. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.08.024 · Cited by 133
Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis
Lu, W., Li, S., Li, J., Wang, J., Zhang, R., Zhou, Y., Yin, Q., Zheng, Y., Wang, F., Xia, Y., et al. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/1459790 · Cited by 130
Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
Nogueira, M. A., de Oliveira, C. P. M. S., Alves, V. A. F., Stefano, J. T., Rodrigues, L., Torrinhas, R. S., Cogliati, B., Barbeiro, H. V., Carrilho, F. J., & Waitzberg, D. L. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2015.05.001 · Cited by 123
Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease
Musa‐Veloso, K., Venditti, C. C., Lee, H. Y., Darch, M., Floyd, S., West, S., & Simon, R. R. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy022 · Cited by 123
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
Byrne, C. D., & Targher, G. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14484 · Cited by 125
Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
Santos, R. D., Valenti, L. V. C., & Romeo, S. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.029 · Cited by 115
Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease
Eslamparast, T., Tandon, P., & Raman, M. (2017) · Nutrients · doi:10.3390/nu9080800 · Cited by 109
Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial
Scorletti, E., West, A. L., Bhatia, L. S., Hoile, S. P., McCormick, K. G., Burdge, G. C., Lillycrop, K. A., Clough, G. F., Calder, P. C., & Byrne, C. D. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.036 · Cited by 115
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
Roeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 108
Mediterranean diet and NAFLD: what we know and questions that still need to be answered
Plaz Torres, M. C., Aghemo, A., Lleo, A., Bodini, G., Furnari, M., Marabotto, E., Miele, L., & Giannini, E. G. (2019) · Nutrients · doi:10.3390/nu11122971 · Cited by 97
Nonalcoholic fatty liver disease
Hardy, T., Anstee, Q. M., & Day, C. P. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000175 · Cited by 95
Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
Iturbe-Rey, S., Maccali, C., Arrese, M. A., Aspichueta, P., de Oliveira, C. P. M. S., Castro, R. E., Lapitz, A., Izquierdo‐Sánchez, L., Bujanda, L., Perugorria, M. J., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119053 · Cited by 102
Unlocking gut-liver-brain axis communication metabolites: energy metabolism, immunity and barriers
Sun, X., Shukla, M., Wang, W., & Li, S. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00610-9 · Cited by 101
Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
Hydes, T., Ravi, S., Loomba, R. S., & Gray, M. E. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0067 · Cited by 90
Potential for Dietary ω-3 Fatty Acids to Prevent Nonalcoholic Fatty Liver Disease and Reduce the Risk of Primary Liver Cancer
Jump, D. Β., Depner, C. M., Tripathy, S., & Lytle, K. A. (2015) · Advances in Nutrition · doi:10.3945/an.115.009423 · Cited by 84
Effect of Omega‐3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD
Smid, V., Dvořák, K., Šedivý, P., Kosek, V., Leníček, M., Dezortová, M., Hajšlová, J., Hájek, M., Vı́tek, L., Bechyňská, K., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1906 · Cited by 78
Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease
Valenzuela, R., Ortíz, M., Hernández‐Rodas, M. C., Echeverría, F., & Videla, L. A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666190410121716 · Cited by 75
Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials
Guo, X., Yang, B., Tang, J., & Li, D. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.01.003 · Cited by 79
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Ng, C. H., Xiao, J., Lim, W. H., Chin, Y. H., Yong, J. N., Tan, D. J. H., Tay, P., Syn, N., Foo, R., Chan, M., et al. (2022) · Hepatology · doi:10.1002/hep.32315 · Cited by 69
Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid
Yoo, W., Gjuka, D., Stevenson, H. L., Song, X., Shen, H., Yoo, S. Y., Wang, J., Fallon, M. B., Ioannou, G. N., Harrison, S. A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189965 · Cited by 69
Fatty acid synthesis suppresses dietary polyunsaturated fatty acid use
Worthmann, A., Ridder, J., Piel, S., Evangelakos, I., Musfeldt, M., Voß, H., O’Farrell, M., Fischer, A. W., Adak, S., Sundd, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44364-y · Cited by 69
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Hossain, N., Kanwar, P., & Mohanty, S. R. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/7109270 · Cited by 70
Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals
Pepa, G. D., Vetrani, C., Lombardi, G., Bozzetto, L., Annuzzi, G., & Rivellese, A. A. (2017) · Nutrients · doi:10.3390/nu9101065 · Cited by 71
Nutritional Characterization of Sea Bass Processing By-Products
Munekata, P. E. S., Pateiro, M., Domínguez, R., Zhou, J., Barba, F. J., & Lorenzo, J. M. (2020) · Biomolecules · doi:10.3390/biom10020232 · Cited by 66
Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice
Lytle, K. A., Wong, C. P., & Jump, D. Β. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173376 · Cited by 62
HCV targeting of patients with cirrhosis
Ferenci, P., Kozbial, K., Mandorfer, M., & Hofer, H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.003 · Cited by 61
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD)
Sawangjit, R., Chongmelaxme, B., Phisalprapa, P., Saokaew, S., Thakkinstian, A., Kowdley, K. V., & Chaiyakunapruk, N. (2016) · Medicine · doi:10.1097/md.0000000000004529 · Cited by 61
Red Meat Consumption and Risk of Nonalcoholic Fatty Liver Disease in a Population With Low Meat Consumption: The Golestan Cohort Study
Hashemian, M., Merat, S., Poustchi, H., Jafari, E., Radmard, A.-R., Kamangar, F., Freedman, N. D., Hekmatdoost, A., Sheikh, M., Boffetta, P., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001229 · Cited by 57
Future therapy for non‐alcoholic fatty liver disease
Issa, D., Patel, V. A., & Sanyal, A. J. (2018) · Liver International · doi:10.1111/liv.13676 · Cited by 58
Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
Sharma, M., Premkumar, M., Kulkarni, A. V., Kumar, P., Reddy, D. N., & Rao, N. P. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00055 · Cited by 54
Metabolic indices of polyunsaturated fatty acids: current evidence, research controversies, and clinical utility
Davinelli, S., Intrieri, M., Corbi, G., & Scapagnini, G. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1724871 · Cited by 57
Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial
Parker, H. M., Cohn, J. S., O'Connor, H. T., Garg, M. L., Caterson, I. D., George, J., & Johnson, N. A. (2019) · Nutrients · doi:10.3390/nu11020475 · Cited by 52
Metabolic Dysfunction–Associated Steatotic Liver Disease
Ali, S. M. J., & Lai, M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02933 · Cited by 57
NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
Caldwell, S. H. (2017) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0103 · Cited by 52
The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: A systematic review and meta-analysis of RCTs
Yu, L., Yuan, M., & Wang, L. (2017) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.334.12315 · Cited by 53
Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease
Gupta, V. K. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10621 · Cited by 50
Normal weight dyslipidemia: Is it all about the liver?
Ipsen, D. H., Tveden‐Nyborg, P., & Lykkesfeldt, J. (2016) · Obesity · doi:10.1002/oby.21443 · Cited by 51
Antifibrotics in chronic liver disease: tractable targets and translational challenges
Ramachandran, P., & Henderson, N. C. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30110-8 · Cited by 52
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Wijarnpreecha, K., Aby, E. S., Ahmed, A., & Kim, D. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0239 · Cited by 52
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease
Chew, N., Ng, C. H., Muthiah, M. D., & Sanyal, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01027-5 · Cited by 49
Associations of serum n–3 and n–6 polyunsaturated fatty acids with prevalence and incidence of nonalcoholic fatty liver disease
Mäkelä, T. N., Tuomainen, T., Hantunen, S., & Virtanen, J. K. (2022) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac150 · Cited by 52
Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids
Spahis, S., Álvarez, F., Ahmed, N., Dubois, J., El-Jalbout, R., Paganelli, M., Grzywacz, K., DELVIN, E. E., Peretti, N., & Levy, E. H. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.03.025 · Cited by 49
Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD
Perumpail, B. J., Li, A. A., Iqbal, U., Sallam, S., Shah, N. D., Kwong, W., Cholankeril, G. T., Kim, D., & Ahmed, A. (2018) · Diseases · doi:10.3390/diseases6030080 · Cited by 48
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
Sohn, W., Lee, Y., Kim, S. S., Kim, J. H., Jin, Y., Kim, G., Sung, P. S., Yoo, J., Chang, Y. W., Lee, E. J., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0045 · Cited by 53
Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
Nobili, V., Alisi, A., Musso, G., Scorletti, E., Calder, P. C., & Byrne, C. D. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1092106 · Cited by 47
Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr mice by targeting the TGFβ-Smad3 pathway
Lytle, K. A., Depner, C. M., Wong, C. P., & Jump, D. B. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m061275 · Cited by 45
Consenso mexicano de la enfermedad por hígado graso no alcohólico
Bernal-Reyes, R., Castro‐Narro, G., Malé-Velázquez, R., Carmona-Sánchez, R., González-Huezo, M. S., García-Juárez, I., Chávez-Tapia, N. C., Aguilar-Salinas, C., Aiza-Haddad, I., Ballesteros-Amozurrutia, M. A., et al. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2018.11.007 · Cited by 52
Eicosapentaenoic Acid Ameliorates Non-Alcoholic Steatohepatitis in a Novel Mouse Model Using Melanocortin 4 Receptor-Deficient Mice
Konuma, K., Itoh, M., Suganami, T., Kanai, S., Nakagawa, N., Sakai, T., Kawano, H., Hara, M., Kojima, S., Izumi, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121528 · Cited by 43
Cholesterol is a significant risk factor for non-alcoholic steatohepatitis
Walenbergh, S. M. A., & Shiri‐Sverdlov, R. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1092382 · Cited by 41
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis
Corey, K. E., & Rinella, M. E. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4083-8 · Cited by 41
Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease
Arendt, B. M., Teterina, A. A., Pettinelli, P., Comelli, E. M., David, W. L., Fung, S. K., McGilvray, I. D., Fischer, S. E., & Allard, J. P. (2018) · Nutrition · doi:10.1016/j.nut.2018.12.001 · Cited by 40

Authors: Argo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., Binder, L. P., Simmons-Egolf, W. D., Burks, S. G., Bao, Y., Taylor, A. G., Rodriguez, J., & Caldwell, S. H.
Affiliations: University of Virginia Health System (US)
University of Virginia (US)
Medical University of Graz (AT)
University of Calgary (CA)
Corresponding author: Argo, Curtis K.
Caldwell, Stephen H.
ORCID: Argo, Curtis K.
Patrie, James T.
Lackner, Carolin
Weltman, Arthur L.
Shah, Neeral L.
Pramoonjago, Patcharin
Jayakumar, Saumya
Binder, Lukas P.
Burks, Sandra G.
Bao, Yongde
Caldwell, Stephen H.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2015-01
Volume: 62
Issue: 1
Pages: 190-197
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2014.08.036
PMC: PMC4272639
OpenAlex: W2019810874
Cited by: 224
References: 37
Citations by year: 2026: 7 · 2025: 16 · 2024: 17 · 2023: 21 · 2022: 13 · 2021: 21 · 2020: 17 · 2019: 16 · 2018: 30 · 2017: 24 · 2016: 19 · 2015: 21
FWCI: 16.41
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: University of Virginia
National Center for Research Resources (5 M01 RR00847, M01RR000847)
National Center for Complementary and Integrative Health (R21AT002901, 5R21AT2901-2)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: omega-3 polyunsaturated fatty acids, nonalcoholic steatohepatitis, liver fat, weight change, exercise capacity, insulin sensitivity, hepatocyte injury, non-cirrhotic liver disease
MeSH terms: Adult, Aged, Biopsy, Double-Blind Method, Energy Metabolism, Female, Follow-Up Studies, Humans, Liver, Male, Middle Aged, Retrospective Studies, Fatty Acids, Omega-3, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks